Contact:
4008465777
-
About Us
News & Events
-
10-27
Tonghua Dongbao records 41.28% YoY increase in net profit attributable to parent company for first 3Qs
On the evening of October 27, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its quarterly report for Q3 2021. In...
-
10-21
Tonghua Dongbao's Insulin Aspart, as part of basal-bolus therapy, approved for sale in China
Tonghua Dongbao's Insulin Aspart Injection (tradename: Ruisulin) was approved for sale in China the other day, adding another member to the Company's insulin analog family since the launch of ...
-
10-20
Tonghua Dongbao wins 2021 China ESG Award for Best Environment Case
On October 19, 2021, the 2021 CLS ESG Summit Forum was held in Shanghai by Cailianshe (CLS) under the guidance of Shanghai United Media Group. Tonghua Dongbao won the 2021 China ESG Award for Best Env...
-
10-20
Tonghua Dongbao receives registration approval for Insulin Aspart and Sitagliptin Metformin Tablets (II)
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or the "Company") received the Registration Approval for Insulin Aspart and Sitagliptin Metformin Tablets (II) from the National M...
-
10-12
Tonghua Dongbao: BC Lispro is approved for parallel Phase III and Phase I clinical trials
On 28 March 2021, Tonghua Dongbao Pharmaceutical Co., Ltd. (the Company or Tonghua Dongbao) submitted to the Center for Drug Evaluation of the National Medical Products Administration (the CDE) an app...
-
10-20
Tonghua Dongbao announces NMPA acceptance of its clinical trial application for URAT1 inhibitor (THDBH130 Tablets)
On 11 October 2021, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the Company or Tonghua Dongbao),recei...